Los Angeles Capital Management & Equity Research Inc. lifted its stake in shares of Haemonetics Corporation (NYSE:HAE) by 222.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 53,889 shares of the medical instruments supplier’s stock after purchasing an additional 37,160 shares during the quarter. Los Angeles Capital Management & Equity Research Inc. owned about 0.10% of Haemonetics Corporation worth $2,128,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Gotham Asset Management LLC bought a new position in shares of Haemonetics Corporation during the 1st quarter worth about $641,000. AXA bought a new position in shares of Haemonetics Corporation during the 1st quarter worth about $292,000. BlackRock Inc. boosted its position in shares of Haemonetics Corporation by 48,854.9% during the 1st quarter. BlackRock Inc. now owns 6,289,728 shares of the medical instruments supplier’s stock worth $255,175,000 after purchasing an additional 6,276,880 shares in the last quarter. Arizona State Retirement System boosted its position in shares of Haemonetics Corporation by 1.1% during the 2nd quarter. Arizona State Retirement System now owns 27,397 shares of the medical instruments supplier’s stock worth $1,082,000 after purchasing an additional 300 shares in the last quarter. Finally, State of Tennessee Treasury Department boosted its position in shares of Haemonetics Corporation by 17.8% during the 1st quarter. State of Tennessee Treasury Department now owns 48,488 shares of the medical instruments supplier’s stock worth $1,967,000 after purchasing an additional 7,318 shares in the last quarter.

Shares of Haemonetics Corporation (HAE) opened at 42.29 on Friday. The company has a 50 day moving average of $42.14 and a 200-day moving average of $40.82. Haemonetics Corporation has a 12-month low of $32.76 and a 12-month high of $43.77. The firm has a market cap of $2.22 billion, a price-to-earnings ratio of 549.22 and a beta of 0.89.

Haemonetics Corporation (NYSE:HAE) last announced its earnings results on Monday, August 7th. The medical instruments supplier reported $0.33 earnings per share for the quarter, beating analysts’ consensus estimates of $0.31 by $0.02. The firm had revenue of $211.00 million for the quarter, compared to analyst estimates of $211.29 million. Haemonetics Corporation had a net margin of 0.48% and a return on equity of 11.07%. The company’s revenue for the quarter was up .5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.25 EPS. Analysts predict that Haemonetics Corporation will post $1.60 EPS for the current year.

TRADEMARK VIOLATION WARNING: “Haemonetics Corporation (HAE) Shares Bought by Los Angeles Capital Management & Equity Research Inc.” was originally published by Daily Political and is the property of of Daily Political. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright & trademark laws. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/09/17/haemonetics-corporation-hae-shares-bought-by-los-angeles-capital-management-equity-research-inc.html.

A number of equities analysts have recently issued reports on the stock. Zacks Investment Research cut shares of Haemonetics Corporation from a “buy” rating to a “hold” rating in a research report on Wednesday, August 16th. JMP Securities raised shares of Haemonetics Corporation from a “market perform” rating to an “outperform” rating and set a $50.00 price objective on the stock in a research report on Thursday, July 13th. BidaskClub raised shares of Haemonetics Corporation from a “strong sell” rating to a “sell” rating in a research report on Tuesday, August 8th. Jefferies Group LLC reissued a “buy” rating and set a $48.00 price objective on shares of Haemonetics Corporation in a research report on Thursday, July 27th. Finally, TheStreet raised shares of Haemonetics Corporation from a “c” rating to a “b-” rating in a research report on Monday, August 7th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and three have issued a buy rating to the company’s stock. Haemonetics Corporation currently has an average rating of “Hold” and an average price target of $40.71.

Haemonetics Corporation Company Profile

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Institutional Ownership by Quarter for Haemonetics Corporation (NYSE:HAE)

Receive News & Ratings for Haemonetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.